Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...
Intas Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive op...
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommen...
The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...
Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, announces that the U...
– Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromata...
Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China wil...
Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...
Shuttle Pharmaceuticals Holdings, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients tr...
Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therap...
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's off...
© 2025 Biopharma Boardroom. All Rights Reserved.
